However, a phase II trial demonstrated that a strategy of dual inhibition of TNF and IL-17A with remtolumab does not appear to be significantly different from that of TNF inhibition alone with adalimumab in human patients with RA and psoriatic arthritis68. This evidence concerns the gene IL17A and rheumatoid arthritis.